KR102275112B1 - 5-브로모-인디루빈 - Google Patents

5-브로모-인디루빈 Download PDF

Info

Publication number
KR102275112B1
KR102275112B1 KR1020157027506A KR20157027506A KR102275112B1 KR 102275112 B1 KR102275112 B1 KR 102275112B1 KR 1020157027506 A KR1020157027506 A KR 1020157027506A KR 20157027506 A KR20157027506 A KR 20157027506A KR 102275112 B1 KR102275112 B1 KR 102275112B1
Authority
KR
South Korea
Prior art keywords
unsubstituted
substituted
compound
cancer
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157027506A
Other languages
English (en)
Korean (ko)
Other versions
KR20160006669A (ko
Inventor
리차드 조베
상길 남
데이비드 혼
준 시에
알렉시오스 레안드로스 스칼츠소니스
마리나 크리츠사니다
콜라르 니콜라스 가보리아우드
Original Assignee
시티 오브 호프
내셔널 앤드 카포디스트리안 유니버시티 오브 아테네
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시티 오브 호프, 내셔널 앤드 카포디스트리안 유니버시티 오브 아테네 filed Critical 시티 오브 호프
Publication of KR20160006669A publication Critical patent/KR20160006669A/ko
Application granted granted Critical
Publication of KR102275112B1 publication Critical patent/KR102275112B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157027506A 2013-03-14 2014-03-14 5-브로모-인디루빈 Expired - Fee Related KR102275112B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783290P 2013-03-14 2013-03-14
US61/783,290 2013-03-14
PCT/US2014/028730 WO2014153023A1 (en) 2013-03-14 2014-03-14 5-bromo-indirubins

Publications (2)

Publication Number Publication Date
KR20160006669A KR20160006669A (ko) 2016-01-19
KR102275112B1 true KR102275112B1 (ko) 2021-07-08

Family

ID=51581389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027506A Expired - Fee Related KR102275112B1 (ko) 2013-03-14 2014-03-14 5-브로모-인디루빈

Country Status (12)

Country Link
US (4) US20160068517A1 (enExample)
EP (1) EP2970310B1 (enExample)
JP (1) JP6422936B2 (enExample)
KR (1) KR102275112B1 (enExample)
CN (1) CN105283456B (enExample)
AU (1) AU2014236370C1 (enExample)
BR (1) BR112015023383A2 (enExample)
CA (1) CA2902914A1 (enExample)
EA (1) EA035877B1 (enExample)
IL (1) IL240916A0 (enExample)
MX (1) MX2015013021A (enExample)
WO (1) WO2014153023A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015013021A (es) 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
AU2018358582B2 (en) * 2017-10-31 2021-06-10 Pelemed Co., Ltd. Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107466A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
WO2007099402A2 (en) * 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications
WO2010013168A1 (en) * 2008-08-01 2010-02-04 Centre National De La Recherche Scientifique (Cnrs) 3',6-substituted indirubins and their biological applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2801216A1 (fr) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
EP2733140A4 (en) 2011-07-15 2014-11-26 Univ Nihon INDIRUBINE DERIVATIVE WITH HIGHLY SELF-ACTIVE CYTOTOXICITY FOR POOR TUMORS
US10435367B2 (en) * 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
MX2015013021A (es) * 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107466A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
WO2007099402A2 (en) * 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications
WO2010013168A1 (en) * 2008-08-01 2010-02-04 Centre National De La Recherche Scientifique (Cnrs) 3',6-substituted indirubins and their biological applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
논문 : Bioorganic & Medicinal Chemistry, Vol. 14, pp. 6434-6443 (2006)*
논문 : Chemistry & Biodiversity, Vol. 9, pp. 2175-2185 (2012)*

Also Published As

Publication number Publication date
US20180170915A1 (en) 2018-06-21
CN105283456B (zh) 2018-12-18
IL240916A0 (en) 2015-10-29
US11306072B2 (en) 2022-04-19
EP2970310A1 (en) 2016-01-20
MX2015013021A (es) 2016-07-14
CA2902914A1 (en) 2014-09-25
BR112015023383A2 (pt) 2017-07-18
KR20160006669A (ko) 2016-01-19
JP6422936B2 (ja) 2018-11-14
US20220274964A1 (en) 2022-09-01
HK1220197A1 (zh) 2017-04-28
WO2014153023A1 (en) 2014-09-25
EP2970310A4 (en) 2016-09-07
JP2016514160A (ja) 2016-05-19
AU2014236370C1 (en) 2019-01-17
US20200283421A1 (en) 2020-09-10
US20160068517A1 (en) 2016-03-10
EA201591709A1 (ru) 2016-03-31
EP2970310B1 (en) 2020-11-11
AU2014236370A1 (en) 2015-09-17
EA035877B1 (ru) 2020-08-25
CN105283456A (zh) 2016-01-27
AU2014236370B2 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
US11964941B2 (en) 5-Bromo-indirubins
JP6342805B2 (ja) 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US11730736B2 (en) Anticancer agents
US20220274964A1 (en) 5-bromo-indirubins
US9862693B2 (en) Compounds and methods of treating cancer
US20230127630A1 (en) Igf2bp2 inhibitors and uses thereof
US20230135758A1 (en) Elongation factor 1-alpha inhibitors and uses thereof
WO2020176349A1 (en) Nnythiosemicarbazone compounds and uses thereof
US11213510B2 (en) Thioindirubins
AU2021276673A1 (en) Notch inhibitors and uses thereof
HK1220197B (en) 5-bromo-indirubins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240703

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240703